Long-term serum spike protein persistence but no 1

correlation with post-COVID syndrome 2

3 Authors:

Annick Fehrer^{1*}, Franziska Sotzny¹, Friederike Hoheisel¹, Elisa Stein¹, Laura Kim¹, Claudia 4 5 Kedor¹, Helma Freitag¹, Cornelia Heindrich¹, Sandra Bauer¹, Rebekka Rust^{1,2}, Martina Seifert^{1,3}, Patricia Grabowski¹, Nina Babel^{1,3,4}, Carmen Scheibenbogen¹, Kirsten Wittke¹ 6

7 Affiliations:

8 ¹ Institute for Medical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 9 Berlin and Humboldt Universität zu Berlin; Berlin, Germany

10 ² Experimental and Clinical Research Center and Neuro Science Clinical Research Center, Charité -

11 Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin; Berlin, 12 Germany

13 ³ Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin; 14 Berlin, Germany

15 ⁴ Center for Translational Medicine and Immune Diagnostics Laboratory, University Hospital of the Ruhr-University 16 Bochum; Herne, Germany

*Corresponding author. Email: annick.fehrer@charite.de 17

18

19 One sentence summary: Our study identified serum spike protein in a subset of patients after

SARS-CoV-2 infection without evidence for a role in the pathogenesis of PCS. 20

Abstract 21

22 According to the World Health Organization (WHO) and the Centers for Diseases Control and

Prevention (CDC), currently an estimated 3 – 6 % of people suffer from post-COVID condition 23

or syndrome (PCS). A subset meets diagnostic criteria for myalgic encephalomyelitis/chronic 24

fatigue syndrome (ME/CFS). Several studies have reported persistence of SARS-CoV-2 25

- 26 proteins or RNA in serum or tissues of both recovered individuals and PCS patients.
- 27 In this exploratory study, we investigated whether serum spike protein is associated with PCS

28 and whether it correlates with symptom severity and laboratory biomarkers. We analyzed

- 29 serum spike protein levels in 121 PCS patients following mild-to-moderate COVID-19, 72 of
- 30 whom met diagnostic criteria for ME/CES (post-COVID ME/CES) pcMECES)

seronegative healthy controls (ppHC, n = 32) and post-COVID recovered healthy controls
(pcHC, n = 37) after SARS-CoV-2 infection were also included in the study.

We found persistent serum SARS-CoV-2 spike protein in a subset of pcHC (11 %), PCS non-ME/CFS patients (2 %), and pcMECFS patients (14 %). There was no significant association with disease severity, symptoms, or laboratory markers. The spike protein concentration was independent of the time since last spike exposure (infection or vaccination). In five spikepositive out of a total of 22 patients who underwent immunoglobulin depletion via immunoadsorption (IA), spike protein was reduced or completely removed after treatment, indicating binding to immunoglobulins.

In summary, our study identified serum spike protein in a subset of patients after SARS-CoV-2
infection without evidence for a role in the pathogenesis of PCS.

42 Key words: COVID-19, Chronic fatigue syndrome, Long COVID, Post-COVID syndrome,
43 Spike protein, SARS-CoV-2, Viral persistence

44

45 **1 Introduction**

Post-COVID syndrome (PCS) refers to persistent symptoms that occur within three months of a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and last for more than two months according to the World Health Organization (WHO) definition (1). It affects individuals across a broad demographic spectrum but is particularly prevalent among young and middle-aged women. PCS is a major burden for health care, economics, and society with an estimated 3 - 6% of patients suffering from chronic and often debilitating illness and no causal therapy so far (1-4).

53 PCS is multisystemic, affects various bodily functions, and presents with a variety of symptoms 54 that include fatigue, exercise intolerance with post-exertional malaise (PEM), cognitive 55 impairments, headaches, muscle pain, and autonomic dysfunction among others. The clinical 56 trajectory can be persistent, relapsing, or fluctuating, significantly impairing the quality of life

and work capacity for many affected individuals. A subset of PCS patients meets the Canadian
consensus (CCC) or Institute of Medicine (IOM) criteria for the diagnosis of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) (5-7).

Although the exact pathomechanisms remain unclear, there are numerous studies providing evidence for inflammation, antibody-mediated autoimmunity, vascular inflammation and circulatory dysfunction, Epstein-Barr-Virus (EBV) reactivation, as well as SARS-CoV-2 persistence in PCS (*8*, *9*).

64 While in the majority of individuals infected with SARS-CoV-2 the virus is successfully cleared 65 from the respiratory tract and blood within one to two weeks in correspondence with resolution 66 of clinical symptoms, a subset of patients experience a prolonged viral persistence or 67 reactivation (10). In these patients, recurrent episodes of viral shedding, as well as persisting 68 viral RNA or spike antigen are believed to contribute to continued activation of immune 69 responses, possibly inducing persistent tissue inflammation (10, 11). Contrary to common 70 perception of coronavirus disease 2019 (COVID-19) as a respiratory disease, SARS-CoV-2 71 cell tropism was not only identified in lungs and trachea but also in the kidneys, pancreas, 72 brain, heart, skin, blood vessels, and small intestines (12). Apart from primary infection of 73 respiratory epithelium via angiotensin converting enzyme 2 (ACE-2) and co-receptor 74 transmembrane protease serine subtype 2 (TMPRSS2), other cell types like gastrointestinal 75 epithelia, endothelial cells, and neurons may also be susceptible to infection (10). 76 SARS-CoV-2 RNA was detected in non-respiratory tissues, including the brain, up to several 77 months after infection (13, 14). Furthermore, several studies report a persistent gastrointestinal 78 viral reservoir in some patients with and without persistent symptoms for up to 2 years (15-17). 79 Spike protein subunit 1 (S1) was found in CD16+ monocytes of PCS patients up to 15 months 80 after acute COVID-19 (11). Peluso et al. showed persistence of SARS-CoV-2 antigen and most commonly spike protein in plasma for more than one year after infection in about 9.2 % of 81 82 specimens, but longitudinal symptoms were not documented in this study (18). Others reported 83 persistent spike protein in the plasma of PCS patients for up to twelve months after infection 84 with a prevalence of up to 60 %, while no spike protein was detected in 26 recovered controls

85 in one study (19) or less frequent in recovered controls in another study (20). Haddad et al. 86 recently reported an ongoing immune response against SARS-CoV-2 antigens evident from 87 newly activated antibody-secreting cells, suggesting viral persistence or reactivation in 40 % of 61 analyzed PCS patients and none of 25 analyzed recovered controls studied (21). 88 89 However, these studies did not explicitly match time points of SARS-CoV-2 infection or 90 vaccination of their study groups and did not document potential reinfections in the time frame 91 investigated. In addition, studies often lack comprehensive patient characterization and 92 classification as well as correlation with clinical data, or they do not include sufficient controls 93 to contextualize results and verify assay specificity (17-23).

To this date, the relationship between PCS and viral persistence is not resolved. Here, we quantified spike protein in serum of PCS patients, as well as pre-pandemic and recovered healthy controls, and analyzed a potential correlation of viral persistence with clinical manifestation and symptom severity. In addition, we investigated the effect of immunoglobulin depletion via immunoadsorption (IA) on serum spike protein in 22 post-COVID ME/CFS (pcMECFS) patients treated in our study as reported elsewhere (*24, 25*).

100

101 **2 Results**

102 **2.1 Persistent spike protein is detectable in serum of individuals after**

103 SARS-CoV-2 infection

SARS-CoV-2 spike receptor-binding domain (RBD) was quantified by ELISA in serum of three post-COVID cohorts: 37 post-COVID recovered healthy controls (pcHC), and 121 PCS patients, of whom 72 met ME/CFS diagnostic criteria (pcMECFS), 1 to 38 months after their last SARS-CoV-2 infection. Additionally, a cohort of 32 pre-pandemic healthy controls (ppHC) was analyzed to validate assay specificity (Fig. 1). While all ppHC serum samples tested negative for SARS-CoV-2 spike protein, 11 % of the pcHC serum samples, 2 % of PCS non-ME/CFS serum samples, and 14 % of the pcMECFS serum samples were positive (Fig. 1A).

Both frequency and spike protein concentration (Fig. 1B) did not differ significantly between the three post-COVID cohorts. However, when comparing PCS with pcMECFS patients separately, there was a significant difference in concentration (p=0.0303) and prevalence of spike protein in serum (p=0.0261).



115

Fig. 1 Serum spike RBD concentration of pre-pandemic healthy controls (ppHC), post-COVID healthy controls (pcHC), post-COVID syndrome (PCS) patients, and post-COVID ME/CFS (pcMECFS) patients. Spike RBD was quantified in serum of ppHC (n=32), pcHC (n=37), PCS patients (n=49), and pcMECFS patients (n=72). (A) Frequency of spike RBD positive (black) and spike RBD negative (grey) individuals in the different study cohorts. Percentages inside the bars indicate frequency of spike-positive individuals. (B) Individual serum spike RBD concentration [pg/ml] of study cohorts. ns=not significant.

123 **2.2 Serum spike protein concentration is independent of the time**

124 since last SARS-CoV-2 spike protein contact

Next, we examined a potential relationship between SARS-CoV-2 spike protein detection and
time since last infection or vaccination in all three post-COVID study groups (pcHC, PCS,
pcMECFS). Neither the time since the last SARS-CoV-2 infection (Fig. 2A), time since last

128 SARS-CoV-2 vaccination (Fig. 2B), nor time since last spike protein contact by either infection 129 or vaccination (Fig. 2C) correlated with the serum spike protein concentration. Furthermore, 130 there was no correlation between time since illness-triggering SARS-CoV-2 infection and 131 serum spike protein concentration in PCS and pcMECFS patients (Fig. 2D). Two out of ten 132 spike-positive pcMECFS patients were vaccinated against SARS-CoV-2 shortly before their 133 visit (three and 13 weeks respectively). Among the spike-negative individuals, five pcMECFS 134 and four PCS patients were vaccinated within six weeks before their visit, and four pcMECFS 135 and four PCS patients within 16 weeks before their visit. Two spike-negative patients had a 136 SARS-CoV-2 infection seven or twelve weeks prior.



137

138 Fig. 2. Correlation analysis of spike RBD in serum of post-COVID study groups with time 139 since SARS-CoV-2 infection or vaccination. Spike RBD concentration in serum of pcHC 140 (n=37), PCS patients (n=49), and pcMECFS patients (n=72) was correlated with (A) the time 141 since last SARS-CoV-2 infection, (B) the time since the last SARS-CoV-2 vaccination, (C) the 142 time since the last contact with spike protein either during SARS-CoV-2 infection or 143 vaccination, and (D) the duration of illness for patients. Correlation was assessed using 144 Spearman's rank-order correlation.

2.3 Serum spike protein is not associated with pcMECFS disease and 145

symptom severity 146

147 Persistent viral reservoirs in PCS is presumed to be associated with inflammation and 148 hypercoagulability, which may contribute to impaired blood flow, endothelial dysfunction, and 149 PCS symptoms (8, 10, 26). To evaluate the possible effect of viral persistence in pcMECFS. 150 we investigated a potential association between persisting serum spike protein and severity of 151 disease and key symptoms comparing ten spike-positive and 62 spike-negative pcMECFS 152 patients. We observed no significant difference in severity of disability, assessed by Bell and 153 Short Form Health Survey 36 (SF-36) physical function scores, nor in PEM score, severity of fatigue, pain, cognitive, immune, or autonomic symptoms, as assessed by Composite 154 155 Autonomic Symptom Score 31 (COMPASS-31), between spike-positive and spike-negative 156 pcMECFS patients (Table 1). The 49 PCS patients were not analyzed as there was only one 157 spike-positive patient in this study group.

158 A subset of pcMECFS patients had elevated interleukin-8 (IL-8) and a few had elevated 159 D-dimer, platelet count, or mean platelet volume (MPV) as potential markers of endothelial 160 inflammation or hypercoagulation. Levels of these markers were not associated with serum 161 spike persistence in our study cohort (Table 2A). Patients who were treated within the IA study 162 had elevated levels of β 2 adrenergic receptor autoantibodies (β 2-AdR-AABs). We did not find 163 significant differences in levels of β2-AdR-AABs between spike-positive and spike-negative 164 pcMECFS, nor in levels of anti-S1-IgG (Table 2B). In six of 21 pcMECFS patients we had 165 evidence for endothelial dysfunction assessed by reactive hyperemia index (RHI) using 166 postocclusive reactive hyperaemia peripheral arterial tonometry (RH-PAT), but no association 167 with spike persistence was observed (Table 2C).

2.4 Serum spike protein is reduced by IA and not associated with IA 168

response 169

170 Twenty-two of the pcMECFS patients studied here were treated with IA for immunoglobulin 171 depletion (IA-pcMECFS) as reported elsewhere (24, 25). Levels of SARS-CoV-2 spike protein

were measured before and four weeks after IA (Fig. 3). Interestingly, in all five patients with detectable serum spike protein, levels were either reduced in two or no longer detectable in three patients four weeks after IA. Patient #17 had a SARS-CoV-2 infection immediately before the four weeks after IA visit. Three of the five spike-positive IA patients were responders and two were non-responders as defined by improvement in their physical function (SF-36) four weeks after IA (*24, 25*). Thus, we have no evidence that there is an association between spike protein serum persistence and clinical response to immunoglobulin depletion.



Fig. 3. Spike RBD concentration in serum of post-COVID ME/CFS (pcMECFS) patients before immunoadsorption (IA) (IA-pcMECFS) and four weeks after IA. Patients who responded to IA are indicated by dotted black and those who did not by white background based on the improvement in SF-36 physical function four weeks after therapy. Spike RBD concentration [pg/ml] in patients' serum was determined before (blue bar) and four weeks after IA (black bar).

186

187 **3 Discussion**

Our study shows persistence of spike protein in serum up to 31 months after infection in a
subset of PCS patients and pcHC. We found neither an association with PCS nor with severity

of disease and symptoms in the pcMECFS subgroup. Moreover, we found no link to markersof endothelial dysfunction, inflammation, or hypercoagulation.

192 The finding from our and other studies of absence of viral proteins in pre-pandemic samples 193 provides strong evidence for the specificity of the detection of viral proteins after SARS-CoV-2 194 infection in a subset of individuals. The prevalence of antigen persistence in serum in our study 195 is consistent with a previous study by Peluso et al. reporting 9.2 % positivity in 660 pandemic-196 era plasma samples up to 14 months after SARS-CoV-2 infection (18). Other studies report 197 lower or higher levels of viral antigen persistence in serum or plasma ranging from no 198 detectable antigen in both PCS and pcHC study groups to a prevalence of approximately 60 % 199 in PCS patients and 0-30 % in pcHCs (19, 20, 22, 27, 28). A recent study reported an 200 association between persistence of SARS-CoV-2 RNA and PCS symptoms up to four months 201 after COVID-19 (29). Other studies suggested that tissue viral persistence is associated with 202 PCS symptoms (17, 30). Notably, our study shows no association between persistent spike 203 protein and symptom severity in pcMECFS patients 2-38 months after their last SARS-CoV-2 204 infection. We found spike protein in only 2 % of PCS patients with a significant difference to 205 pcMECFS patients. However, as we detected spike protein in 11 % of pcHC, we consider it 206 more likely to be a random rather than a pathomechanistically relevant finding.

207 Spike protein can promote microvascular inflammation and thrombogenic processes (*31, 32*), 208 but our study did not find a correlation between endothelial dysfunction, thromboinflammatory 209 markers, and spike protein persistence in pcMECFS patients. In line with our findings, others 210 didn't observe a link between SARS-CoV-2 persistent shedding in saliva and PCS 211 development or symptoms (*33*). The heterogeneity of findings in the various studies may be 212 related to the generally low levels of viral proteins, potential cross-reactivity with other proteins 213 and different tests that were used.

The hypothesis of viral persistence playing a role in the pathomechanism of PCS is currently used as a rationale for antiviral treatment studies. Paxlovid, a drug consisting of the antiviral agents nirmatrelvir and ritonavir, has been shown to be effective in preventing a severe course

217 of COVID-19 (34), which is associated with an increased risk of PCS (35, 36). Findings from a 218 study using a large dataset of >281,000 participants from the US Department of Veterans 219 Affairs suggested a protective effect of Paxlovid treatment during acute COVID-19 also for the 220 development of PCS (37), while other smaller studies couldn't reproduce these findings (38, 221 39). A first randomized placebo-controlled trial of 155 PCS patients in the STOP-PASC study 222 showed no significant effect of 15 days of Paxlovid treatment on persistent symptoms (40). 223 However, in this study viral particles were not assessed; thus, it is not possible to draw 224 conclusions about the subgroup of patients with evidence of viral persistence.

In addition, our data show a reduction or removal of serum spike protein after immunoglobulin depletion via IA. This suggests that spike protein is bound to anti-spike IgG. However, it cannot be excluded that there is an unspecific binding of spike protein with the antibody-specific sepharose gel matrix used for the IA procedure. The presence or reduction of serum spike protein was not associated with treatment response. This further suggests that persistent spike protein is not causing symptoms in these pcMECFS patients.

The present study has some limitations that need to be addressed. It is a cross-sectional study, that provides a snapshot of serum spike persistence. Temporal profiling of SARS-CoV-2 antigens in the plasma of PCS patients shows fluctuating concentration profiles of both spike and nucleocapsid protein over a time period of up to twelve months after infection (*19*). Regular blood sampling within a defined time frame and interval would be necessary to shed further light on the mechanisms of viral persistence and its temporal detectability in serum.

We determined the concentration of spike protein RBD in the serum. This is worth mentioning, as a previous study reported discrepancies between e.g. S1 and full spike protein detection (*19*). In addition, spike protein may not only be present in a soluble form, but may also be transported in extracellular vesicles, as previously reported (*20, 41*). Other studies have shown persistence of viral RNA in tissues (*13-17*). This should be taken into account for interpretation of the results presented here.

As PCS is a highly heterogeneous disease, viral persistence may play a role only in the pathogenesis of certain subtypes of PCS. Our study focused on a subgroup of patients with

ME/CFS or similar symptom complexes. Further research is needed to elucidate potential differences in spike persistence in clinically and immunologically distinct PCS subtypes and its potential relevance for the diagnosis and treatment of patients.

In conclusion, despite the limitations described, our study provides evidence for serum spike
 persistence in a subset of individuals after SARS-CoV-2 infection without an association with
 PCS.

- 251
- 252 4 Material and Methods

253 4.1 Study design, study cohorts, and symptom assessment

We conducted an exploratory, cross-sectional study investigating serum spike persistence in individuals with and without PCS symptoms up to 38 months after SARS-CoV-2 infection. The study aimed to determine whether serum spike protein is associated with PCS symptoms or correlates with disease severity and selected laboratory markers.

258 Serum samples and clinical data from 121 PCS patients suffering from moderate to severe 259 fatigue and exertion intolerance following mostly mild COVID-19 were collected between 260 October 2020 and January 2024 at the ME/CFS outpatient clinic of the Institute of Medical Immunology, Charité, Berlin. From these, 72 met the CCC for diagnosis of ME/CFS 261 262 (pcMECFS) (42, 43). Relevant cardiac, respiratory, neurological, or psychiatric comorbidities 263 were excluded. We analyzed 22 pcMECFS patients who had participated in an observational 264 study of immunoglobulin depletion via IA (IA-pcMECFS) (24, 25). Of these, serum samples at 265 timepoints before and four weeks after IA were analyzed.

Additionally, serum samples from 37 pcHC five to twelve months after their last SARS-CoV-2 infection were obtained between January 2023 and October 2023. pcHCs did not suffer from a disease with relevant impairment or take regular medication, and had no infection or vaccination within the last four weeks. To control for assay specificity, 32 pre-pandemic serum samples from ppHC, collected between January 2019 and October 2019, were analyzed.

271 Cohort characteristics are listed in Table 3. The IA-pcMECFS study group differed significantly from the other study groups due to a longer disease duration, as well as longer time after 272 SARS-CoV-2 infection and vaccination. Severity of disease and symptoms were quantified 273 274 using questionnaires. PEM was assessed according to Cotler et al. 2018 with scores ranging 275 from 0 to 46 (no to frequent, severe, long lasting PEM) (44). Functional ability was scored using 276 the Bell Disability Scale ranging from 0 to 100 (total loss of self-dependence to no restrictions) 277 (45). Daily physical activities were assessed using the SF-36 ranging from 0 to 100 (greatest 278 to no restrictions) (46). The severity of the cardinal symptoms fatigue, cognitive impairment, 279 immune symptoms, and pain were quantified using a Likert scale (1 = no symptoms to 10 = 280 most severe symptoms). Symptoms of autonomic dysfunction were assessed using the 281 COMPASS-31 ranging from 0 to 100 (no to strongest symptoms) (47). As evident from the Bell 282 score, patients with pcMECFS suffered from more severe disease compared to PCS non-283 ME/CFS patients, while clinical presentation of pcMECFS and IA-pcMECFS study groups were 284 comparable (Table 3). Ethical Committee approval for this project was obtained in accordance 285 with the 1964 Declaration of Helsinki and its later amendments (EA2/066/20 and EA2/067/20). 286 All study participant signed informed consent before study inclusion.

4.2 Quantification of serum spike RBD and anti-S1 IgG

288 Whole blood samples from participants were allowed to clot at room temperature for at least 289 30 min and then centrifuged at 2000 x g for 10 min at room temperature. Serum was collected 290 and stored at -80°C. Serum concentration of the SARS-CoV-2 spike RBD was determined 291 using Human SARS-CoV-2 RBD ELISA Kit purchased from Thermo Fisher Scientific 292 (EH492RB) and conducted according to manufacturer's instructions. Serum anti-S1 IgG was 293 quantified using anti-SARS-CoV-2 QuantiVac ELISA (IgG) purchased from Euroimmun (EI 294 2606-9601-10 G) and conducted according to manufacturer's instructions. Obtained arbitrary 295 units (AU) were converted into the WHO International Standard (IS) for anti-SARS-CoV-2 296 immunoglobulin binding activity (Binding Antibody Units, BAU) by multiplying by a factor of 3.2.

4.3 Assessment of routine laboratory and functional parameters

298 D-Dimer, platelet count, MPV, and IL-8 (post erythrocyte lysis) were determined at the Charité

299 diagnostics laboratory Labor Berlin GmbH (Berlin, Germany). Autoantibodies (AABs) against

- 300 the G protein coupled receptor (GPCR) β2 adrenergic receptor (β2-AdR), were determined by
- 301 CellTrend GmbH (Luckenwalde, Germany) using indirect ELISA technology.
- 302 Peripheral endothelial function was assessed in IA-pcMECFS patients by the RHI using RH-
- 303 PAT (endoPAT2000, Itamar Medical Ltd., Caesarea, Israel) as previously described (48).

304 4.4 Data Collection and Management

Study data, including clinical and routine laboratory parameters, were collected and managed
using REDCap electronic data capture tools hosted at Charité—Universitätsmedizin Berlin (*49*, *50*).

308 4.5 Statistical analysis

309 Study data are presented as median with range or interquartile range (IQR) for each study 310 group (n = number of individuals in the study group) as indicated. Nonparametric statistical 311 methods were used. Univariate comparisons of two independent groups were done using the 312 Mann-Whitney-U test and of multiple independent groups using the Kruskal-Wallis test with 313 Benjamini-Hochberg correction of multiple comparisons. Distribution of categorical data was 314 compared using chi-square test. Correlation was assessed using Spearman's rank-order 315 correlation. A two-tailed p value <0.05 was considered significant. Microsoft Excel 2016 was 316 used for data analysis and GraphPad Prism 9 was used for statistical analysis and graphical 317 presentation.

318

319 **5 Acknowledgements**

320 We would like to thank the patients who participated in this study, as well as Anja Hagemann,

321 Silvia Thiel, and Beate Follendorf for their work in patient care and data management.

- Funding: This study was funded by the ME/CFS Research foundation and the Lost Voicesfoundation. AF received a scholarship from the Fridericus foundation.
- 324 Author contributions: AF conducted the laboratory work and data analysis of the study. ES, 325 LK, CK, RR, PG, KW, and CS diagnosed and enrolled the patients, and collected the 326 biosamples. AF, FH, and SB collected biosamples of healthy controls and processed all 327 biosamples. FS, HF, and CH managed clinical and routine laboratory data. FS, KW, and CS 328 provided concept, resources, and supervision. AF, FS, and CS interpreted and discussed the 329 results. AF, FS, MS, NB, CS, and KW provided scientific insights. AF, FS, and CS wrote the 330 manuscript. All authors have read, revised, and approved the final version of the manuscript. 331 Competing interests: The authors declare no conflict of interest.
- 332 **Data and materials availability:** All data associated with this study are present in the paper.
- 333 Correspondence and requests should be addressed to AF (<u>annick.fehrer@charite.de</u>).

334 6 References

- J. B. Soriano, S. Murthy, J. C. Marshall, P. Relan, J. V. Diaz, A clinical case definition
 of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 22, e102-e107
 (2022).
- 338 2. E. J. Thompson, D. M. Williams, A. J. Walker, R. E. Mitchell, C. L. Niedzwiedz, T. C.
- 339 Yang, C. F. Huggins, A. S. F. Kwong, R. J. Silverwood, G. Di Gessa, R. C. E. Bowyer,
- 340 K. Northstone, B. Hou, M. J. Green, B. Dodgeon, K. J. Doores, E. L. Duncan, F. M. K.
- 341 Williams, A. Steptoe, D. J. Porteous, R. R. C. McEachan, L. Tomlinson, B. Goldacre,
- 342 P. Patalay, G. B. Ploubidis, S. V. Katikireddi, K. Tilling, C. T. Rentsch, N. J. Timpson,
- N. Chaturvedi, C. J. Steves, Long COVID burden and risk factors in 10 UK longitudinal
 studies and electronic health records. *Nat Commun* 13, 3528 (2022).
- N. D. Ford, D. Slaughter, D. Edwards, A. Dalton, C. Perrine, A. Vahratian, S. Saydah,
 Long COVID and Significant Activity Limitation Among Adults, by Age United States,
 June 1-13, 2022, to June 7-19, 2023. *MMWR Morb Mortal Wkly Rep* 72, 866-870
 (2023).
- A. Iba, M. Hosozawa, M. Hori, Y. Muto, I. Muraki, R. Masuda, N. Tamiya, H. Iso,
 Prevalence of and Risk Factors for Post-COVID-19 Condition during Omicron BA.5 Dominant Wave, Japan. *Emerg Infect Dis* **30**, 1380-1389 (2024).
- C. Kedor, H. Freitag, L. Meyer-Arndt, K. Wittke, L. G. Hanitsch, T. Zoller, F. Steinbeis,
 M. Haffke, G. Rudolf, B. Heidecker, T. Bobbert, J. Spranger, H. D. Volk, C. Skurk, F.
 Konietschke, F. Paul, U. Behrends, J. Bellmann-Strobl, C. Scheibenbogen, A
 prospective observational study of post-COVID-19 chronic fatigue syndrome following
 the first pandemic wave in Germany and biomarkers associated with symptom severity.
 Nat Commun 13, 5104 (2022).
- R. Twomey, J. DeMars, K. Franklin, S. N. Culos-Reed, J. Weatherald, J. G. Wrightson,
 Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An
 Observational Study. *Phys Ther* **102**, 1-12 (2022).

361 7. E. R. Unger, J. S. Lin, L. E. Wisk, H. Yu, M. L'Hommedieu, H. Lavretsky, J. C. C.

362 Montoy, M. A. Gottlieb, K. L. Rising, N. L. Gentile, M. Santangelo, A. K. Venkatesh, R.

- 363 M. Rodriguez, M. J. Hill, R. E. Geyer, E. R. Kean, S. Saydah, S. A. McDonald, R.
- 364 Huebinger, A. H. Idris, J. Dorney, B. Hota, E. S. Spatz, K. A. Stephens, R. A. Weinstein,
- 365 J. G. Elmore, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-
- 366 2 Infection. JAMA Netw Open 7, e2423555 (2024).
- 367 8. H. E. Davis, L. McCorkell, J. M. Vogel, E. J. Topol, Long COVID: major findings,
 368 mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133-146 (2023).
- 369 9. Y. Su, D. Yuan, D. G. Chen, R. H. Ng, K. Wang, J. Choi, S. Li, S. Hong, R. Zhang, J.
- 370 Xie, S. A. Kornilov, K. Scherler, A. J. Pavlovitch-Bedzyk, S. Dong, C. Lausted, I. Lee,
- 371 S. Fallen, C. L. Dai, P. Baloni, B. Smith, V. R. Duvvuri, K. G. Anderson, J. Li, F. Yang,
- 372 C. J. Duncombe, D. J. McCulloch, C. Rostomily, P. Troisch, J. Zhou, S. Mackay, Q.
- 373 DeGottardi, D. H. May, R. Taniguchi, R. M. Gittelman, M. Klinger, T. M. Snyder, R.
- 374 Roper, G. Wojciechowska, K. Murray, R. Edmark, S. Evans, L. Jones, Y. Zhou, L.
- 375 Rowen, R. Liu, W. Chour, H. A. Algren, W. R. Berrington, J. A. Wallick, R. A. Cochran,
- 376 M. E. Micikas, T. Wrin, C. J. Petropoulos, H. R. Cole, T. D. Fischer, W. Wei, D. S. B.
- Hoon, N. D. Price, N. Subramanian, J. A. Hill, J. Hadlock, A. T. Magis, A. Ribas, L. L.
- 378 Lanier, S. D. Boyd, J. A. Bluestone, H. Chu, L. Hood, R. Gottardo, P. D. Greenberg, M.
- 379 M. Davis, J. D. Goldman, J. R. Heath, Multiple early factors anticipate post-acute
- 380 COVID-19 sequelae. *Cell* **185**, 881-895.e820 (2022).
- B. Chen, B. Julg, S. Mohandas, S. B. Bradfute, R. M. P. T. Force, Viral persistence,
 reactivation, and mechanisms of long COVID. *eLife* 12, e86015 (2023).
- 383 11. B. K. Patterson, E. B. Francisco, R. Yogendra, E. Long, A. Pise, H. Rodrigues, E. Hall,
- 384 M. Herrera, P. Parikh, J. Guevara-Coto, T. J. Triche, P. Scott, S. Hekmati, D. Maglinte,
- 385 X. Chang, R. A. Mora-Rodríguez, J. Mora, Persistence of SARS CoV-2 S1 Protein in
- 386 CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-
- 387 Infection. *Frontiers in Immunology* **12**, 746021 (2022).

- J. Liu, Y. Li, Q. Liu, Q. Yao, X. Wang, H. Zhang, R. Chen, L. Ren, J. Min, F. Deng, B.
 Yan, L. Liu, Z. Hu, M. Wang, Y. Zhou, SARS-CoV-2 cell tropism and multiorgan
 infection. *Cell Discovery* 7, 17 (2021).
- 391 13. S. R. Stein, S. C. Ramelli, A. Grazioli, J.-Y. Chung, M. Singh, C. K. Yinda, C. W.
- 392 Winkler, J. Sun, J. M. Dickey, K. Ylaya, S. H. Ko, A. P. Platt, P. D. Burbelo, M. Quezado,
- 393 S. Pittaluga, M. Purcell, V. J. Munster, F. Belinky, M. J. Ramos-Benitez, E. A. Boritz, I.
- A. Lach, D. L. Herr, J. Rabin, K. K. Saharia, R. J. Madathil, A. Tabatabai, S. Soherwardi,
- 395 M. T. McCurdy, A. L. Babyak, L. J. Perez Valencia, S. J. Curran, M. E. Richert, W. J.
- 396 Young, S. P. Young, B. Gasmi, M. Sampaio De Melo, S. Desar, S. Tadros, N. Nasir, X.
- Jin, S. Rajan, E. Dikoglu, N. Ozkaya, G. Smith, E. R. Emanuel, B. L. Kelsall, J. A.
- 398 Olivera, M. Blawas, R. A. Star, N. Hays, S. Singireddy, J. Wu, K. Raja, R. Curto, J. E.
- 399 Chung, A. J. Borth, K. A. Bowers, A. M. Weichold, P. A. Minor, M. A. N. Moshref, E. E.
- 400 Kelly, M. M. Sajadi, T. M. Scalea, D. Tran, S. Dahi, K. B. Deatrick, E. M. Krause, J. A.
- 401 Herrold, E. S. Hochberg, C. R. Cornachione, A. R. Levine, J. E. Richards, J. Elder, A.
- 402 P. Burke, M. A. Mazzeffi, R. H. Christenson, Z. A. Chancer, M. Abdulmahdi, S. Sopha,
- 403 T. Goldberg, Y. Sangwan, K. Sudano, D. Blume, B. Radin, M. Arnouk, J. W. Eagan, R.
- 404 Palermo, A. D. Harris, T. Pohida, M. Garmendia-Cedillos, G. Dold, E. Saglio, P. Pham,
- 405 K. E. Peterson, J. I. Cohen, E. de Wit, K. M. Vannella, S. M. Hewitt, D. E. Kleiner, D.
- 406 S. Chertow, N. C.-A. Consortium, SARS-CoV-2 infection and persistence in the human
- 407 body and brain at autopsy. *Nature* **612**, 758-763 (2022).
- J. Matschke, M. Lütgehetmann, C. Hagel, J. P. Sperhake, A. S. Schröder, C. Edler, H.
 Mushumba, A. Fitzek, L. Allweiss, M. Dandri, M. Dottermusch, A. Heinemann, S.
 Pfefferle, M. Schwabenland, D. Sumner Magruder, S. Bonn, M. Prinz, C. Gerloff, K.
 Püschel, S. Krasemann, M. Aepfelbacher, M. Glatzel, Neuropathology of patients with
 COVID-19 in Germany: a post-mortem case series. *The Lancet Neurology* **19**, 919-929
 (2020).
- 414 15. C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho,
 415 M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes,

Y. Bram, G. Breton, T. Hägglöf, P. Mendoza, A. Hurley, M. Turroja, K. Gordon, K. G.
Millard, V. Ramos, F. Schmidt, Y. Weisblum, D. Jha, M. Tankelevich, G. MartinezDelgado, J. Yee, R. Patel, J. Dizon, C. Unson-O'Brien, I. Shimeliovich, D. F. Robbiani,
Z. Zhao, A. Gazumyan, R. E. Schwartz, T. Hatziioannou, P. J. Bjorkman, S. Mehandru,
P. D. Bieniasz, M. Caskey, M. C. Nussenzweig, Evolution of antibody immunity to

- 421 SARS-CoV-2. *Nature* **591**, 639-644 (2021).
- A. Natarajan, S. Zlitni, E. F. Brooks, S. E. Vance, A. Dahlen, H. Hedlin, R. M. Park, A.
 Han, D. T. Schmidtke, R. Verma, K. B. Jacobson, J. Parsonnet, H. F. Bonilla, U. Singh,
 B. A. Pinsky, J. R. Andrews, P. Jagannathan, A. S. Bhatt, Gastrointestinal symptoms
 and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. *Med* 3, 371-387.e379 (2022).
- M. J. Peluso, D. Ryder, R. R. Flavell, Y. Wang, J. Levi, B. H. LaFranchi, T.-M. Deveau,
 A. M. Buck, S. E. Munter, K. A. Asare, M. Aslam, W. Koch, G. Szabo, R. Hoh, M.
 Deswal, A. E. Rodriguez, M. Buitrago, V. Tai, U. Shrestha, S. Lu, S. A. Goldberg, T.
 Dalhuisen, J. J. Vasquez, M. S. Durstenfeld, P. Y. Hsue, J. D. Kelly, N. Kumar, J. N.
- 431 Martin, A. Gambhir, M. Somsouk, Y. Seo, S. G. Deeks, Z. G. Laszik, H. F. VanBrocklin,
- 432 T. J. Henrich, Tissue-based T cell activation and viral RNA persist for up to 2 years 433 after SARS-CoV-2 infection. *Science Translational Medicine* **16**, eadk3295 (2024).
- M. J. Peluso, Z. N. Swank, S. A. Goldberg, S. Lu, T. Dalhuisen, E. Borberg, Y. Senussi,
 M. A. Luna, C. Chang Song, A. Clark, A. Zamora, M. Lew, B. Viswanathan, B. Huang,
 K. Anglin, R. Hoh, P. Y. Hsue, M. S. Durstenfeld, M. A. Spinelli, D. V. Glidden, T. J.
 Henrich, J. D. Kelly, S. G. Deeks, D. R. Walt, J. N. Martin, Plasma-based antigen
 persistence in the post-acute phase of COVID-19. *The Lancet Infectious Diseases* 24,
 e345-e347 (2024).
- Z. Swank, Y. Senussi, Z. Manickas-Hill, X. G. Yu, J. Z. Li, G. Alter, D. R. Walt, Persistent
 Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated
 With Post-acute Coronavirus Disease 2019 Sequelae. *Clin Infect Dis* **76**, e487-e490
 (2023).

V. Craddock, A. Mahajan, L. Spikes, B. Krishnamachary, A. K. Ram, A. Kumar, L.
Chen, P. Chalise, N. K. Dhillon, Persistent circulation of soluble and extracellular
vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. *J Med Virol* 95, e28568 (2023).

- 448 21. N. S. Haddad, A. Morrison-Porter, H. Quehl, V. Capric, P. A. Lamothe, F. Anam, M. C.
- 449 Runnstrom, A. D. Truong, A. N. Dixit, M. C. Woodruff, A. Chen, J. Park, D. C. Nguyen,
- 450 I. Hentenaar, C. Y. Kim, S. Kyu, B. Stewart, E. Wagman, H. Geoffroy, D. Sanz, K. S.
- 451 Cashman, R. P. Ramonell, M. Cabrera-Mora, D. N. Alter, J. D. Roback, M. C. Horwath,
- J. B. O'Keefe, A. W. Dretler, R. Gripaldo, S. M. Yeligar, T. Natoli, V. Betin, R. Patel, K.
- 453 Vela, M. R. Hernandez, S. Usman, J. Varghese, A. Jalal, S. Lee, S. N. Le, R. T. Amoss,
- J. L. Daiss, I. Sanz, F. E. Lee, MENSA, a Media Enriched with Newly Synthesized
 Antibodies, to Identify SARS-CoV-2 Persistence and Latent Viral Reactivation in LongCOVID. *medRxiv*, DOI:10.1101/2024.1107.1105.24310017 (2024).
- N. Kanberg, A. Grahn, E. Stentoft, D. Bremell, A. Yilmaz, M. Studahl, S. Nilsson, M.
 Schöll, J. M. Gostner, K. Blennow, H. Zetterberg, N. Padmanabhan, R. Cohen, S.
 Misaghian, D. Romero, C. Campbell, A. Mathew, M. Wang, G. Sigal, M. Stengelin, A.
 Edén, M. Gisslén, COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid
- Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications. *The Journal of Infectious Diseases* 229, 493-501 (2023).
- 463 23. A. Zollner, R. Koch, A. Jukic, A. Pfister, M. Meyer, A. Rössler, J. Kimpel, T. E. Adolph,
 464 H. Tilg, Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in
 465 Inflammatory Bowel Diseases. *Gastroenterology* **163**, 495-506.e498 (2022).
- 466 24. E. Stein, C. Heindrich, K. Wittke, C. Kedor, L. Kim, H. Freitag, A. Krüger, M. Tölle, C.
 467 Scheibenbogen, Observational Study of Repeat Immunoadsorption (RIA) in Post468 COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An
 469 Interim Report. *J Clin Med* **12**, 6428 (2023).
- 470 25. E. Stein, C. Heindrich, K. Wittke, C. Kedor, R. Rust, H. Freitag, F. Sotzny, A. Krüger,
 471 M. Tölle, P. Grabowski, C. Scheibenbogen, L. Kim, Efficacy of Repeat

472 Immunoadsorption in Post-COVID ME/CFS Patients with Elevated β2-Adrenergic
473 Receptor Autoantibodies: a Prospective Cohort Study. *Available at SSRN:*474 *https://ssrn.com/abstract=4911576*, (2024).

- 475 26. I. Katsoularis, O. Fonseca-Rodríguez, P. Farrington, H. Jerndal, E. H. Lundevaller, M.
 476 Sund, K. Lindmark, A. M. Fors Connolly, Risks of deep vein thrombosis, pulmonary
 477 embolism, and bleeding after covid-19: nationwide self-controlled cases series and
 478 matched cohort study. *Bmj* **377**, e069590 (2022).
- S. M. Menezes, M. Jamoulle, M. P. Carletto, L. Moens, I. Meyts, P. Maes, J. Van
 Weyenbergh, Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and
 candidate biomarkers in post-COVID-19 condition. *The Lancet Microbe* 5, 100849
 (2024).
- 483 28. A. Rahmati, S. Shahbaz, M. Osman, J. W. C. Tervaert, S. Elahi, Blood transcriptomic
 484 analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19
 485 condition with chronic fatigue syndrome. *The Lancet Microbe* **0**, 101012 (2024).
- 486 29. W. Zuo, D. He, C. Liang, S. Du, Z. Hua, Q. Nie, X. Zhou, M. Yang, H. Tan, J. Xu, Y.
- 487 Yu, Y. Zhan, Y. Zhang, X. Gu, W. Zhu, H. Zhang, H. Li, W. Sun, M. Sun, X. Liu, L. Liu,
- 488 C. Cao, R. Li, J. Li, Y. Zhang, Y. Zhang, J. Guo, L. Zhao, C.-P. Zhang, H. Liu, S. Wang,
- F. Xiao, Y. Wang, Z. Wang, H. Li, B. Cao, The persistence of SARS-CoV-2 in tissues
 and its association with long COVID symptoms: a cross-sectional cohort study in China. *The Lancet Infectious Diseases* 24, 845-855 (2024).
- G. D. de Melo, F. Lazarini, S. Levallois, C. Hautefort, V. Michel, F. Larrous, B. Verillaud,
 C. Aparicio, S. Wagner, G. Gheusi, L. Kergoat, E. Kornobis, F. Donati, T. Cokelaer, R.
 Hervochon, Y. Madec, E. Roze, D. Salmon, H. Bourhy, M. Lecuit, P. M. Lledo, COVID19-related anosmia is associated with viral persistence and inflammation in human
 olfactory epithelium and brain infection in hamsters. *Sci Transl Med* 13, eabf8396
 (2021).
- 498 31. L. Perico, M. Morigi, A. Pezzotta, M. Locatelli, B. Imberti, D. Corna, D. Cerullo, A.
 499 Benigni, G. Remuzzi, SARS-CoV-2 spike protein induces lung endothelial cell

500 dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling.

501 *Scientific Reports* **13**, 11392 (2023).

- 502 32. A. C. Montezano, L. L. Camargo, S. Mary, K. B. Neves, F. J. Rios, R. Stein, R. A.
- 503 Lopes, W. Beattie, J. Thomson, V. Herder, A. M. Szemiel, S. McFarlane, M. Palmarini,
- 504 R. M. Touyz, SARS-CoV-2 spike protein induces endothelial inflammation via ACE2

505 independently of viral replication. *Scientific Reports* **13**, 14086 (2023).

- 506 33. M. J. Peluso, A. N. Deitchman, L. Torres, N. S. Iyer, S. E. Munter, C. C. Nixon, J.
- 507 Donatelli, C. Thanh, S. Takahashi, J. Hakim, K. Turcios, O. Janson, R. Hoh, V. Tai, Y.
- 508 Hernandez, E. A. Fehrman, M. A. Spinelli, M. Gandhi, L. Trinh, T. Wrin, C. J.

509 Petropoulos, F. T. Aweeka, I. Rodriguez-Barraguer, J. D. Kelly, J. N. Martin, S. G.

- 510 Deeks, B. Greenhouse, R. L. Rutishauser, T. J. Henrich, Long-term SARS-CoV-2-511 specific immune and inflammatory responses in individuals recovering from COVID-19 512 with and without post-acute symptoms. *Cell Reports* **36**, 109518 (2021).
- J. Hammond, H. Leister-Tebbe, A. Gardner, P. Abreu, W. Bao, W. Wisemandle, M.
 Baniecki, V. M. Hendrick, B. Damle, A. Simón-Campos, R. Pypstra, J. M. Rusnak, Oral
 Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine* 386, 1397-1408 (2022).
- 517 35. Y. Xie, B. Bowe, Z. Al-Aly, Burdens of post-acute sequelae of COVID-19 by severity of 518 acute infection, demographics and health status. *Nat Commun* **12**, 6571 (2021).
- 519 36. E. L. Hill, H. B. Mehta, S. Sharma, K. Mane, S. K. Singh, C. Xie, E. Cathey, J. Loomba,
 520 S. Russell, H. Spratt, P. E. DeWitt, N. Ammar, C. Madlock-Brown, D. Brown, J. A.
 521 McMurry, C. G. Chute, M. A. Haendel, R. Moffitt, E. R. Pfaff, T. D. Bennett, Risk factors
 522 associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER
 523 study. *BMC Public Health* 23, 2103 (2023).
- 524 37. Y. Xie, T. Choi, Z. Al-Aly, Association of Treatment With Nirmatrelvir and the Risk of 525 Post–COVID-19 Condition. *JAMA Internal Medicine* **183**, 554-564 (2023).
- 526 38. M. S. Durstenfeld, M. J. Peluso, F. Lin, N. D. Peyser, C. Isasi, T. W. Carton, T. J.
 527 Henrich, S. G. Deeks, J. E. Olgin, M. J. Pletcher, A. L. Beatty, G. M. Marcus, P. Y.

- Hsue, Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent
 Long COVID symptoms in an observational cohort study. *J Med Virol* 96, e29333
 (2024).
- S. Congdon, Z. Narrowe, N. Yone, J. Gunn, Y. Deng, P. Nori, K. Cowman, M. Islam, S.
 Rikin, J. Starrels, Nirmatrelvir/ritonavir and risk of long COVID symptoms: a
 retrospective cohort study. *Sci Rep* 13, 19688 (2023).
- 534 40. L. N. Geng, H. Bonilla, H. Hedlin, K. B. Jacobson, L. Tian, P. Jagannathan, P. C. Yang, 535 A. K. Subramanian, J. W. Liang, S. Shen, Y. Deng, B. J. Shaw, B. Botzheim, M. Desai, 536 D. Pathak, Y. Jazayeri, D. Thai, A. O'Donnell, S. Mohaptra, Z. Leang, G. Z. M. 537 Reynolds, E. F. Brooks, A. S. Bhatt, R. W. Shafer, M. G. Miglis, T. Quach, A. Tiwari, A. 538 Banerjee, R. N. Lopez, M. De Jesus, L. R. Charnas, P. J. Utz, U. Singh, Nirmatrelvir-539 Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: 540 The STOP-PASC Randomized Clinical Trial. JAMA Intern Med 184, 1024-1034 (2024). 541 Z. Troyer, N. Alhusaini, C. O. Tabler, T. Sweet, K. I. L. de Carvalho, D. M. Schlatzer, L. 41.
- 542 Carias, C. L. King, K. Matreyek, J. C. Tilton, Extracellular vesicles carry SARS-CoV-2 543 spike protein and serve as decoys for neutralizing antibodies. *J Extracell Vesicles* **10**, 544 e12112 (2021).
- 545 42. B. M. Carruthers, A. K. Jain, K. L. De Meirleir, D. L. Peterson, N. G. Klimas, A. M.
 546 Lerner, A. C. Bested, P. Flor-Henry, P. Joshi, A. C. P. Powles, J. A. Sherkey, M. I. van
 547 de Sande, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Journal of Chronic*548 *Fatigue Syndrome* **11**, 7-115 (2003).
- L. A. Jason, M. Evans, N. Porter, M. Brown, A. Brown, J. Hunnell, V. Anderson, A.
 Lerch, K. De Meirleir, F. Friedberg, The Development of a Revised Canadian Myalgic
 Encephalomyelitis Chronic Fatigue Syndrome Case Definition. *American Journal of Biochemistry and Biotechnology* 6, 120-135 (2010).
- 553 44. J. Cotler, C. Holtzman, C. Dudun, L. A. Jason, A Brief Questionnaire to Assess Post554 Exertional Malaise. *Diagnostics (Basel)* 8, 66 (2018).

- 555 45. D. S. Bell, *The doctor's guide to chronic fatigue syndrome: understanding, treating, and* 556 *living with Cfids.* (Reading, Mass., Addison-Wesley Pub. Co., 1994).
- 557 46. J. E. Ware, Jr., C. D. Sherbourne, The MOS 36-item short-form health survey (SF-36).
- 558 I. Conceptual framework and item selection. *Med Care* **30**, 473-483 (1992).
- 559 47. D. M. Sletten, G. A. Suarez, P. A. Low, J. Mandrekar, W. Singer, COMPASS 31: a
 560 refined and abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc* 87,
 561 1196-1201 (2012).
- M. Haffke, H. Freitag, G. Rudolf, M. Seifert, W. Doehner, N. Scherbakov, L. Hanitsch,
 K. Wittke, S. Bauer, F. Konietschke, F. Paul, J. Bellmann-Strobl, C. Kedor, C.
 Scheibenbogen, F. Sotzny, Endothelial dysfunction and altered endothelial biomarkers
 in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). *J Transl Med* 20, 138 (2022).
- P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, J. G. Conde, Research
 electronic data capture (REDCap)--a metadata-driven methodology and workflow
 process for providing translational research informatics support. *J Biomed Inform* 42,
 377-381 (2009).
- 571 50. P. A. Harris, R. Taylor, B. L. Minor, V. Elliott, M. Fernandez, L. O'Neal, L. McLeod, G.
 572 Delacqua, F. Delacqua, J. Kirby, S. N. Duda, The REDCap consortium: Building an
 573 international community of software platform partners. *J Biomed Inform* **95**, 103208
 574 (2019).
- 575
- 576

7 Tables 577

- 578 Table 1. Comparative analysis of disease and symptom severity in pcMECFS patients
- 579 with (Spike+) or without (Spike-) persistent serum spike RBD.

| Parameter | Spike+ (n=10) | Spike- (n=62) | p-value |
|----------------------------|--------------------------|---------------|---------|
| | median | median | |
| | (range) | (range) | |
| | n | n | |
| Se | everity of disability ar | nd PEM | |
| | 30.00 | 30.00 | |
| Bell Disability Scale | (20.00-40.00) | (10.00-60.00) | 0.7380 |
| | n=10 | n=61 | |
| | 25.00 | 35.00 | |
| SF-36 Physical Functioning | (5.00-50.00) | (0.00-70.00) | 0.1021 |
| | n=10 | n=61 | |
| | 36.00 | 34.00 | |
| PEM score | (29.00-46.00) | (19.00-46.00) | 0.5707 |
| | n=9 | n=58 | |
| | Symptom scores | 3 | |
| | 8.25 | 8.00 | |
| Fatigue score | (6.25-10.00) | (5.5-10.00) | 0.8686 |
| | n=9 | n=59 | |

| | 6.67 | 7.00 | | | |
|-------------------------------------|---------------------------|-------------------------|-------------------|--|--|
| Cognitive score | (1.67-9.33) | (2.33-10.00) | 0.9265 | | |
| | n=9 | n=60 | | | |
| | 2.67 | 3.67 | | | |
| Immune score | (1.00-7.33) | (1.00-8.67) | 0.2961 | | |
| | n=8 | n=58 | | | |
| | 6.00 | 6.50 | | | |
| Headache | (1.00-10.00) | (1.00-10.00) | 0.5623 | | |
| | n=9 | n=60 | | | |
| | 6.00 | 7.00 | | | |
| Muscle pain | (1.00-10.00) | (1.00-10.00) | 0.6602 | | |
| | n=9 | n=60 | | | |
| | 6.00 | 5.00 | | | |
| Joint pain | (1.00-9.00) | (1.00-10.00) | 0.8496 | | |
| | n=9 | n=60 | | | |
| Assessment of autonomic dysfunction | | | | | |
| | 41.51 | 38.25 | | | |
| COMPASS-31 total | (11.55-58.24) | (2.68-76.23) | 0.4045 | | |
| | n=10 | n=59 | | | |
| Mann-Whitney U rank-sum | test was performed to to | est the statistical sig | nificance of the | | |
| difference in numerical data l | between the study groups. | SF-36=Short Form H | lealth Survey 36, | | |
| PEM=post-exertional malaise | e, COMPASS-31=Compos | ite Autonomic Sympto | om Score 31. | | |

584 Table 2. Comparative analysis of routine laboratory and functional markers of pcMECFS

585 patients with (Spike+) or without (Spike-) persistent serum spike RBD.

| Parameter | Reference Range | Spike+ (n=10) Spike- (n=62) | | p-value | |
|-------------------|-------------------------------------|-----------------------------|--------------------|---------|--|
| | | median | median | | |
| | | (IQR) | (IQR) | | |
| | | n(out of reference | n(out of reference | | |
| | | range)/n | range)/n | | |
| A) | Thrombotic and inflammatory markers | | | | |
| | | 126.80 | 131.00 | | |
| IL-8 [pg/ml] | <150.00 | (94.60-132.10) | (106.20-176.90) | 0.2705 | |
| | | 1/7 | 18/55 | | |
| | | 0.21 | 0.23 | | |
| D-Dimer [mg/l] | <0.50 | (0.19-0.34) | (0.19-0.38) | 0.5863 | |
| | | 0/5 | 3/39 | | |
| | | 258.50 | 265.50 | | |
| Platelets [/nl] | 150.00-370.00 | (244.50-277.00) | (220.75-308.50) | 0.9513 | |
| | | 0/8 | 3/60 | | |
| | | 10.90 | 10.70 | | |
| MPV [fl] | 7.00-12.00 | (10.45-11.55) | (10.20-11.60) | 0.5273 | |
| | | 1/8 | 4/60 | | |
| В) | β2-AdR-AAE | 3 and anti-S1 IgG | | | |
| | | 24.15 | 15.63 | | |
| β2-AdR-AAB [a.u.] | <14.00 | (10.2-34.79) | (8.51-24.50) | 0.2613 | |
| | | 6/10 | 31/59 | | |

| anti-S1 IaG [BALI/m]] | 1953.51 | 838.33 | 1185.01 | |
|-----------------------|-------------------|---------------------|------------------|--------|
| | (1034.04-3265.13) | (447.05-1957.15) | (547.86-1944.94) | 0.7382 |
| median, (IQR), n | n=16* | n=10 | n=32 | |
| C) | Markers of e | ndothelial dysfunct | ion | |
| | | 1.78 | 2.08 | |
| RHI | >1.67 | (1.41-2.19) | (1.70-2.37) | 0.4531 |
| | | 2/4 | 4/17 | |

*Median (IQR) of 16 pcHC. Mann-Whitney U rank-sum test was performed to test the statistical
significance of the difference in numerical data between the study groups. IQR= interquartile
range, NA=not assessed, MPV=mean platelet volume, β2-AdR= β2 adrenergic receptor,
AAB=autoantibody, S1=spike protein subunit 1, BAU=Binding Antibody Units, RHI= reactive
hyperemia index.

592 **Table 3. Cohort characteristics**

| Study group | ррНС | рсНС | PCS | pcMECFS | IA-pcMECFS | p-values |
|--------------------|---------|-----------|-----------|-----------|------------|----------------|
| n | 32 | 37 | 49 | 50 | 22 | NA |
| | | | | | | p1=0.2463 |
| | | | | | | p2=0.1484 |
| Age [y], median | 29 | 34 | 37 | 40.5 | 40 | p3=0.0824 |
| (range) | (21-54) | (23-56) | (23-62) | (21-59) | (31-59) | p4=0.6535 |
| (lange) | | | | | | p5=0.3027 |
| | | | | | | p6=0.4243 |
| Female sex [%] | 77.14 | 78.38 | 79.59 | 80.00 | 68.18 | p=0.8230 |
| Duration of | | | | | | p4=0.3443 |
| illness [m], | NA | NA | 9 | 9 | 20 | , p5<0.0001 |
| median | | | (6-14) | (6-17) | (8-41) | p6<0.0001 |
| (range) | | | | | | • |
| Time ofter least | | | | | | p1=0.0679 |
| | | | | | | p2=0.3034 |
| infaction [m] | | 10 | 8 | 9 | 14 | p3=0.2233 |
| modian | INA | (5-12) | (1-13) | (5-12) | (2-38) | p4=0.2819 |
| (range) | | | | | | p5=0.0055 |
| (lange) | | | | | | p6=0.0504 |
| Time ofter least | | | | | | p1=0.0032 |
| SARS-CoV-2 | NA | 16 | 9 | 11.5 | 17 | p2=0.0955 |
| | | (4-22) | (0-20) | (0-24) | (0-24) | p3=0.3700 |
| modion | | 0 unvacc. | 9 unvacc. | 6 unvacc. | 1 unvacc. | p4=0.1049 |
| | | n=24 | n=47 | n=49 | n=20 | p5=0.0004 |
| (range) | | | | | | p6=0.0133 |

| | Bell Disabili | ity | | | | | |
|-----|-----------------|------------------|--------------|------------|-------------------|----------------|---------------------|
| | Scale. | | | 50 | 30 | 30 | p4<0.0001 |
| | | NA | NA | (00 | | | p5<0.0001 |
| | median | | | (30-90) | (10-60) | (20-40) | p6=0.4806 |
| | (range) | | | | | | |
| 593 | Kruskall-Wa | llis rank-sum 1 | est or Mar | nn-Whitney | U rank-sum te | est were perf | ormed to test the |
| 594 | statistical sig | gnificance of th | ne differenc | ce in nume | rical data betwe | en multiple c | or two of the post- |
| 595 | COVID coho | ort groups (pc | HC, PCS, | pcMECFS |) respectively. I | Distribution o | f categorical data |
| 596 | was compar | red using chi- | square tes | st. p1=PCS | 6 vs. pcHC, p2 | epcMECFS | vs pcHC, p3=IA- |
| 597 | pcMECFS v | s pcHC, p4=P | CS vs pcN | /IECFS, p5 | 5=PCS vs IA-po | MECFS, p6= | pcMECFS vs IA- |
| 598 | pcMECFS. | ppHC=pre-pa | indemic h | nealthy co | ontrol, pcHC=p | oost-COVID | healthy control, |
| 599 | PCS=PCS n | ion-ME/CFS, p | cMECFS= | post-COV | ID ME/CFS, IA- | pcMECFS=Ir | nmunoadsorption |
| 600 | pcMECFS (| pcMECFS su | bcohort be | efore IA), | unvacc.=unvac | cinated, y=y | ears, m=months. |

601 Significant differences are highlighted in bold.